## Viral Hepatitis Data From AASLD 2020\*—Rapid Recap

## **Polling Overview**


Produced by Your Conference Live Platform
December 10, 2020, 4:42 AM ET

: How many patients with hepatitis B do you provide care for in a typical wk?

Option Votes Percentage


Total 0

## : How many patients with hepatitis C do you provide care for in a typical wk?




Option < 10	<b>Votes</b> 64	Percentage 71.9%
10-25	20	22.5%
26-50	5	5.6%
51-100	0	0.0%
>100	0	0.0%
	Total 89	

: Presurvey 1: In a retrospective cohort study by Hirode and colleagues evaluating patients with chronic HBV infection who discontinued nucleos(t)ide analogue therapy, which of the following factors was significantly associated with increased likelihood of HBsAg loss on multivariate analysis?



Option Age < 50 yrs vs 50 yrs or older	<b>Votes</b> 5	Percentage 6.2%
Age < 50 yrs vs 50 yrs or older	3	0.2 /0
Treatment with entecavir vs tenofovir DF	14	17.3%
Caucasian vs Asian race	8	9.9%
HBeAg positive vs HBeAg negative at start of therapy	30	37.0%
Unsure	24	29.6%
	Total 81	

: Assessment 1: In a retrospective cohort study by Hirode and colleagues evaluating patients with chronic HBV infection who discontinued nucleos(t)ide analogue therapy, which of the following factors was significantly associated with increased likelihood of HBsAg loss on multivariate analysis?



Option	Votes	Percentage
Age < 50 yrs vs 50 yrs or older	7	8.3%
Treatment with entecavir vs tenofovir DF	8	9.5%
Caucasian vs Asian race	62	73.8%
HBeAg positive vs HBeAg negative at start of therapy	4	4.8%
Unsure	3	3.6%
	Total 84	